58 unknown, 31 completed, 8 recruiting, 6 terminated. 75 Phase 2, 19 Phase 1, 15 Phase 3, 6 Not applicable.
Follow SHR-1210: new trials by email Literature Review of SHR-1210 trials Research Report on SHR-1210
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC Camrelizumab, Paclitaxel, carboplatin - Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Not yet recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2026-02-01 | 2026-02-10 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab Camrelizumab, Chemotherapy, Radiotherapy - Rectal Cancer | Phase 2 | Not yet recruiting | Harbin Medical University | 48 | 2024-03-15 | 2024-03-12 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-11-01 | 2023-11-08 |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 170 | 2023-08-01 | 2023-08-08 |
| A SHR-1210 BE Study on Healthy Subjects SHR-1210 - Advanced Tumors | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2023-07-04 | 2024-12-31 |
| FUSCC Refractory TNBC Platform Study (FUTURE2.0) A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab with famitinib, B1: TROP2 ADC - Triple-negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 120 | 2023-03-30 | 2026-04-16 |
| SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma SBRT, Camrelizumab, Gemcitabine - Nasopharyngeal Carcinoma | Phase 2 | Active not recruiting | Sun Yat-sen University | 41 | 2022-11-25 | 2026-05-07 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
| Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer Camrelizumab, Apatinib Mesylate - Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 68 | 2022-05-01 | 2022-04-22 |
| Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer Camrelizumab, Irinotecan, Paclitaxel - Stage IV Esophagus Squamous Cell Carcinoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 80 | 2022-04-15 | 2022-04-11 |
| Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas Camrelizumab, Etoposide, Carboplatin - Advanced or Metastatic EP-NEC | Phase 2 | Unknown | Huazhong University of Science and Technology | 30 | 2022-01-14 | 2021-12-03 |
| Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer Camrelizumab - Esophageal Cancer | Not applicable | Unknown | The First Affiliated Hospital of Zhengzhou University | 337 | 2022-01-01 | 2021-08-23 |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell Camrelizumab, Apatinib - Esophageal Cancer | Phase 3 | Unknown | Feng Wang | 234 | 2021-12-05 | 2021-09-20 |
| A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma SHR-1210 - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 42 | 2021-10-01 | 2021-08-23 |
| A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Camrelizumab, Famitinib - NSCLC | Phase 2 | Unknown | Shanghai Chest Hospital | 61 | 2021-09-01 | 2021-08-13 |
| Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma Camrelizumab, Famitinib - Sarcomatoid Carcinoma of Lung | Phase 2 | Completed | Qian Chu | 17 | 2021-07-19 | 2026-10-14 |
| Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy Camrelizumab, Apatinib - Advanced Non Squamous NSCLC | Phase 2 | Unknown | Junling Li | 30 | 2021-06-28 | 2021-06-29 |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC Camrelizumab, Cisplatin, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 81 | 2021-06-24 | 2025-07-31 |
Showing 20 of 108. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Esophageal Neoplasms (8) · Stomach Neoplasms (8) · Breast Neoplasms (7) · Nasopharyngeal Carcinoma (7) · Esophageal Squamous Cell Carcinoma (6) · Carcinoma, Hepatocellular (5) · Lung Neoplasms (5) · Recurrence (4) · Uterine Cervical Neoplasms (4) · Lung Diseases (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Respiratory Tract Diseases (3) · Small Cell Lung Carcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3)
Jiangsu HengRui Medicine Co., Ltd. (33) · Sun Yat-sen University (6) · Chinese PLA General Hospital (4) · Fudan University (4) · Tianjin Medical University Cancer Institute and Hospital (4) · Chinese Academy of Medical Sciences (3) · Guangdong Association of Clinical Trials (3) · Henan Cancer Hospital (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · The First Affiliated Hospital of Zhengzhou University (3) · Harbin Medical University (2) · Peking Union Medical College Hospital (2) · Shanghai Zhongshan Hospital (2) · Zhejiang Cancer Hospital (2) · Atridia Pty Ltd. (1)
China (95) · Russia (2) · Australia (1) · Belgium (1) · Germany (1) · Hong Kong (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1) · United States (1)
Feng Wang (3) · Li Zhang, MD (3) · Qing Yang, MD (3) · Erwei Song, M.D., Ph.D. (2) · Jianjun Zou, MD, PhD (2) · Wei Shi, MD (2) · Yanqiao Zhang, PhD (2) · Baohui Han (1) · Baorui Liu, M.D & Ph.D (1) · Caicun Zhou, MD, PhD (1) · Chenping Zhang, M.D. (1) · Chong Zhao, MD. PhD. (1) · Chunbo Zhao, MD (1) · Ding Ma (1) · Dingwei Ye, MD (1)
PMID 30213452, PMID 37409613, PMID 37580352, PMID 15126782, PMID 15875784, PMID 17340590, PMID 22575238, PMID 23452187, PMID 24357284, PMID 24948466, PMID 25800393, PMID 25838374, PMID 25838375, PMID 26515495, PMID 26901407, PMID 27324428, PMID 27827318, PMID 27959684, PMID 28197365, PMID 28408606, PMID 28583311, PMID 28796558, PMID 29368638, PMID 29614760, PMID 30293387, PMID 30348638, PMID 30835255, PMID 31039052, PMID 31420358, PMID 32112738, PMID 32256049, PMID 32376724, PMID 32416073, PMID 32448804, PMID 33052760, PMID 33166719, PMID 33314747, PMID 33347829, PMID 33674274, PMID 33741732, PMID 33766817, PMID 33820822, PMID 34011535, PMID 34174189, PMID 34309846, PMID 34409776, PMID 34519801, PMID 34616588, PMID 34668977, PMID 34923163